Phathom Pharmaceuticals (Nasdaq: PHAT) has received approval from the US regulator for a reformulation of its oral vonoprazan products.
The nod covers the antibiotics Voquenza Triple Pak (vonoprazan/amoxicillin/clarithromycin) and Voquenza Dual Pak (vonoprazan/amoxicillin), which are used to treat Helicobacter pylori infection in adults.
The decision relates to a Prior Approval Supplement (PAS), a regulatory determination regarding a proposed change to the manufacture or testing of a product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze